HCP-1803

Hanmi Pharmaceutical Advances Six New Drugs into Clinical Trials Targeting Hypertension, Diabetes, and Cancer

7 months ago

• Hanmi Pharmaceutical is progressing HCP1803, a novel low-dose triple antihypertensive drug, through Phase 3 clinical trials in Korea, expected to conclude in the second half of next year. • The company launched Raspirin, an antithrombotic drug, this year, expanding its product line to offer diverse treatment options for healthcare providers and patients. • Hanmi's U.S.-based biologic Rolvedon, a cancer drug, generated $55.6 million in sales last year, with ongoing efforts to expand its global reach in Asia, Africa, and the U.S. • Efpeglenatide, a returned biologic drug, will be developed into a Korean-specific GLP-1 obesity drug, with further clinical and non-clinical developments underway.

Hanmi Pharmaceutical Advances Six New Drugs into Clinical Trials Targeting Hypertension, Diabetes, and Cancer

Drug Development Updates